Drug Type Small molecule drug |
Synonyms + [4] |
Target |
Action inhibitors |
Mechanism RPS27 inhibitors(ribosomal protein S27 inhibitors), TTK inhibitors(Dual specificity protein kinase TTK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC35H39F3N8O3 |
InChIKeyJFOAJUGFHDCBJJ-UHFFFAOYSA-N |
CAS Registry1202055-32-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | - | - | |
Metastatic breast cancer | Discovery | France | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | France | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | Japan | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | Netherlands | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | Netherlands | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | Belgium | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | Japan | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | France | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Discovery | Belgium | 04 Jan 2018 |
Phase 1/2 | 12 | (dose-finding) | (gfqvievalv) = wifwpxlozm volgudbnji (znzpiutxek ) View more | Positive | 28 Oct 2022 | ||
Phase 1/2 | - | (uficvqynzp) = jmpqtdhbwv qigsyjwqtv (rszaoidvjp ) View more | Positive | 28 Oct 2022 | |||
Phase 1 | 38 | xtrdcenmsp(fzltjszcjo) = fpkzzkdlti yhpdiqkswp (vvzfhhnetn ) View more | - | 11 May 2022 |